Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN1 | Q9GZT9 | 11/20 | 0.65 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.42 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.42 |
| ▸ | PYGL | P06737 | 1/20 | 0.40 |
| ▸ | VEGFA | P15692 | 2/20 | 0.38 |
| ▸ | FLT1 | P17948 | 2/20 | 0.38 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.38 |
| ▸ | PRKACA | P17612 | 1/20 | 0.38 |
| ▸ | PRKACG | P22612 | 1/20 | 0.38 |
| ▸ | PRKACB | P22694 | 1/20 | 0.38 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | NPBWR1 | P48145 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | CNR2 | P34972 | 1/20 | 0.37 |
| ▸ | EGLN3 | Q9H6Z9 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17154106 | 0.84 | EGLN1 (0.55) | EGLN1ROCK2PRKACAPRKACGPRKACB | |
| SCHEMBL4313112 | 0.81 | EGLN1 (0.57) | EGLN1ROCK2PRKACAPRKACGPRKACB | |
| SCHEMBL4305872 | 0.81 | EGLN1 (0.47) | EGLN1HRH4HRH3VEGFAFLT1 | |
| SCHEMBL4313430 | 0.79 | EGLN1 (0.67) | EGLN1ROCK2PRKACAPRKACGPRKACB | |
| SCHEMBL13626230 | 0.79 | EGLN1 (0.58) | EGLN1HRH4HRH3VEGFAFLT1 | |
| SCHEMBL4309470 | 0.79 | EGLN1 (1.00) | EGLN1HRH4HRH3 | |
| SCHEMBL4307002 | 0.79 | EGLN1 (0.57) | EGLN1SMN1; SMN2 | |
| SCHEMBL4309205 | 0.78 | EGLN1 (0.57) | EGLN1ROCK2PRKACAPRKACGPRKACB | |
| SCHEMBL4308121 | 0.77 | EGLN1 (0.52) | EGLN1VEGFAFLT1EGLN3 | |
| SCHEMBL4305878 | 0.77 | EGLN1 (0.81) | EGLN1HRH4HRH3MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150284335-A1 | Benzoimidazoles as prolyl hydroxylase inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2015-10-08 | — | — | US | claimed |
| WO-2009134754-A1 | BENZOIMIDAZOLE GLYCINAMIDES AS PROLYL HYDROXYLASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2009-11-05 | — | — | WO | claimed |
| US-20150284335-A1 | Benzoimidazoles as prolyl hydroxylase inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2015-10-08 | — | — | US | disclosed |
| US-20150284335-A1 | Benzoimidazoles as prolyl hydroxylase inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2015-10-08 | — | — | US | disclosed |
| US-20150284335-A1 | Benzoimidazoles as prolyl hydroxylase inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2015-10-08 | — | — | US | disclosed |
| WO-2009134754-A1 | BENZOIMIDAZOLE GLYCINAMIDES AS PROLYL HYDROXYLASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2009-11-05 | — | — | WO | disclosed |
| WO-2009134754-A1 | BENZOIMIDAZOLE GLYCINAMIDES AS PROLYL HYDROXYLASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2009-11-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150284335-A1 | Benzoimidazoles as prolyl hydroxylase inhibitors | EGLN3, EGLN2, P4HA1 | EGLN1 5/4885HRH4 1015/4885HRH3 665/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.